Table of Contents: CATIE TreatmentUpdate - 2002


Canadian AIDS Treatment Information Exchange
Edited by: Sean Hosein

Jump to Table of Contents

TreatmentUpdate 130: September/October - Vol. 14, No. 7

English  Françaises
 ANTI-HIV AGENTS - Drug holidays - an overview

 AGENTS ANTI-VIH - Les congés thérapeutiques — un survol

HoseinSR
Dealing with chronic health conditions is never an easy task both for patients and their doctors. Complex treatment regimens, large numbers of pills, side effects and drug interactions are just some of the challenges faced by people taking medications for these conditions. In high-income countries, many people with HIV/AIDS (PHAs) who have received highly active antiretroviral therapy (HAART) face these issues on a daily basis. Not surprisingly, some of these PHAs tire of taking HAART day after day, for many years. As a result, there is much interest in the idea of possibly taking a break from treatment regimens. Such breaks are commonly referred to as "drug holidays" or structured treatment interruptions (STIs).

 ANTI-HIV AGENTS - Here's a story about a drug holiday

 AGENTS ANTI-HIV - L'histoire d'un congé thérapeutique

HoseinSR
Over the past two years, guidelines for starting HAART have become gradually more cautious by suggesting that treatment be initiated later (lower CD4+ counts) rather than earlier (higher CD4+ counts) in the course of HIV disease. Before this change in guidelines, some PHAs began therapy at CD4+ counts that are higher than the presently recommended starting point (for the latest treatment guidelines, go to http://hivatis.org/trtgdlns.html). As a result of early therapy, these PHAs may have had huge increases in CD4+ counts. Some American PHAs who found themselves in this position decided to embark on a closely supervised drug holiday. We now report on this study.

 TOXICITY - Milk thistle and indinavir

 Le chardon-Marie et l'indinavir

HoseinSR
In North America, some people with HIV/AIDS (PHAs) use vitamins, supplements and herbs to complement their drug-based therapy. One complementary therapy that is popular is the herb milk thistle. Traditionally, this herb has been used for the treatment of liver disorders such as jaundice (yellowing of the skin and whites of the eyes). Recent laboratory research on cells suggests that milk thistle extracts may be useful in helping the liver and kidneys recover from damage caused by certain drugs and alcohol.

 TESTING - Some factors affecting survival in HIV positive women

 TESTS - De quels facteurs dépend la survie des femmes séropositives?

HoseinSR
In high-income countries, the use of highly active antiretroviral therapy (HAART) has greatly decreased deaths and illness due to AIDS. However, the benefits of HAART have not been as dramatic in some HIV positive women as they have been in HIV positive men. The reasons for this difference are not clear, but perhaps they involve issues around access to care and treatment.

 ANTI-CANCER AGENTS - A new treatment for Kaposi's sarcoma

 AGENTS ANTICANCÉREUX - Un nouveau traitement contre le sarcome de Kaposi?

HoseinSR
Infection with the virus HHV-8 (human herpes virus-8) can cause a disease called Kaposi's sarcoma (KS). Signs of this disease are the growth of KS lesions on the skin; as well, lesions can merge, particularly inside the body, around lymphatic vessels. This can cause fluid build-up, swelling and pain. In some cases, particularly when KS affects important organs such as the lungs, it can become life threatening.

Table Of Contents

TreatmentUpdate 132: December - Vol. 14, No. 9
INTRODUCTION: What's a conference about ?; SIDE EFFECTS: Who gets treatment and... side effects; SIDE EFFECTS: Protection from nuke side effects; SIDE EFFECTS: Breaking free from nukes; ADHERENCE: What helps adherence to therapy?; VACCINES: Rub-on vaccine study planned; CANCER: Cancer risk falls in some HAART users; INFECTIONS: Syphilis - the great masquerader; INFECTIONS: Is hepatitis C virus going to become a major STD

TreatmentUpdate 131: November - Vol. 14, No. 8
SIDE EFFECTS: The usual suspects; SIDE EFFECTS: A brief history of HIV drug therapy; SIDE EFFECTS: Strange side effects; SIDE EFFECTS: Focus on fat; SIDE EFFECTS: Lots of volunteers needed; SIDE EFFECTS: Lactic acid and nuke damage; SIDE EFFECTS: No nukes please; SIDE EFFECTS: Fat wasting - AZT vs. d4T; SIDE EFFECTS: Sugar blues; SIDE EFFECTS: Predicting body shape changes; SIDE EFFECTS: Niacin for high triglycerides; SIDE EFFECTS: Supplement fix for nelfinavir-related diarrhea

TreatmentUpdate 130: September/October - Vol. 14, No. 7
ANTI-HIV AGENTS - Drug holidays - an overview ; ANTI-HIV AGENTS - Here's a story about a drug holiday ; TOXICITY - Milk thistle and indinavir ; TESTING - Some factors affecting survival in HIV positive women ; ANTI-CANCER AGENTS - A new treatment for Kaposi's sarcoma

TreatmentUpdate 129: August - Vol. 14, No. 6
THE XIV INTERNATIONAL AIDS CONFERENCE - Overview of conferencel; ANTI-HIV AGENTS : American-Italian study produces unexpected results; ANTI-HIV AGENTS : Tenofovir looks good in initial therapy; ANTI-HIV AGENTS : Tenofovir and Videx (ddI) EC — some caution required; ANTI-HIV AGENTS : T-20 shows its potency; ANTI-HIV AGENTS : Efavirenz makes its mark in AIDS; TESTING : Study finds fatigue linked to quality of sleep; TESTING : High liver enzyme levels — a warning about survival?; NUTRITION : Nutrient deficits found in some HIV positive people; NUTRITION : Low zinc intake linked to reduced survival

TreatmentUpdate 128: July - Vol. 14, No. 5
SIDE EFFECTS: Sexual dysfunction in men: A report from France; SIDE EFFECTS: Sexual dysfunction in men: A report from Boston; SIDE EFFECTS: Male sexual dysfunction and HAART — the confusion continues; SIDE EFFECTS: Study finds problems with reporting side effects; ANTI-CANCER AGENTS: Recurring cervical growths; ANTI-HIV AGENTS: Starting therapy: study finds guidelines linked to level of immunity

TreatmentUpdate 127: May/June - Vol. 14, No. 4
ANTI-HIV AGENTS: Delavirdine in rescue regimens; ANTI-HIV AGENTS: Could cimetidine be used as a booster?; ANTI-HIV AGENTS: Teaching adherence to substance users; Fine-tuning saquinavir; ANTI-HIV AGENTS: Invirase vs. Fortovase: unexpected results?; ANTI-HIV AGENTS: Saquinavir once daily; ANTI-HIV AGENTS: Saquinavir with low-dose ritonavir twice daily; ANTI-HIV AGENTS: Highlights from the 3rd International Workshop on Clinical Pharmacology of HIV Therapy

TreatmentUpdate 126: March - Vol. 14, No. 3
SIDE EFFECTS : Protease inhibitors and lipid-lowering drugs -- interactions; Cause of serious illness among HAART-users not clear; Using abacavir to avoid lipid problems; Switching to abacavir to reduce fat wasting; 9th Retrovirus Overview; SIDE EFFECTS : Assessing nuke toxicity; SIDE EFFECTS : Check-ups for the power plant?; SIDE EFFECTS : Damage to the power plant

TreatmentUpdate 125: February - Vol. 14, No. 2
SIDE EFFECTS: Comparing liver toxicity between efavirenz and nevirapine; SIDE EFFECTS: Nevirapine levels may predict toxicity; SIDE EFFECTS: Health Canada advises against kava; SIDE EFFECTS: Birth defect in baby born to efavirenz-user; SIDE EFFECTS: Viagra and grapefruit juice - not a good mix; INFECTION FIGHTERS: Cidofovir and surgery for genital warts; ANTI-HIV AGENTS: Swiss study switching to efavirenz

TreatmentUpdate 124: January - Vol. 14, No. 1
SIDE EFFECTS: Testosterone troubles; SIDE EFFECTS: Growth hormone: Does less equal more?; SIDE EFFECTS: Thyroid troubles in Montreal; SIDE EFFECTS: Thyroid troubles in France; HIGHLIGHTS FROM ICAAC: Directly observed therapy (DOT); HIGHLIGHTS FROM ICAAC: Amprenavir and low-dose ritonavir; HIGHLIGHTS FROM ICAAC: Saquinavir vs. Sustiva once daily; HIGHLIGHTS FROM ICAAC: Tenofovir; HIGHLIGHTS FROM ICAAC: Atazanavir boosts saquinavir; HIGHLIGHTS FROM ICAAC: Atazanavir vs. nelfinavir; HIGHLIGHTS FROM ICAAC: Atazanavir overview; ANTI-HIV AGENTS: Starting HAART and its effect on survival; ANTI-HIV AGENTS: Response to HAART depends on T-cell count; ANTI-HIV AGENTS: Delaying therapy - the pendulum swings back

Copyright / Staff / How to Contact
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2002. ÆGiS . All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS , or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.